Kynexis
Naarden
About Kynexis
Kynexis is advancing the first potential precision medicine for the treatment of cognitive impairment associated with schizophrenia (CIAS).
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $61.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Nov 2023)
- Website: kynexistx.com
Industries & Categories
Biotechnology, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/kynexis-18558 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.